Search results
Morgan Stanley downgrades 8x8 stock to 'Underweight', sees revenue challenges By Investing.com
Investing.com· 9 hours agoOn Friday, Morgan Stanley downgraded 8x8 stock, a provider of voice, video, chat, and contact center...
Cognizant maintains stock target, Equalweight rating on recent acquisition By Investing.com
Investing.com· 4 days agoOn Monday, Morgan Stanley reaffirmed its Equalweight rating on shares of Cognizant Technology...
Morgan Stanley cuts Nestle rating to equal-weight on growth concerns By Investing.com
Investing.com· 4 days agoOn Monday, Nestle SA (SIX:NESN:SW) (OTC: NSRGY (OTC:NSRGY)) experienced a shift in its stock outlook...
Morgan Stanley upgrades CIENA stock, sees FY24 less risky By Investing.com
Investing.com· 2 days agoOn Wednesday, Morgan Stanley adjusted its stance on CIENA (NYSE:CIEN), raising the stock's rating...
Morgan Stanley maintains Equalweight rating on Futu Holdings after bank stake buy By Investing.com
Investing.com· 3 days agoOn Tuesday, Morgan Stanley (NYSE:MS) maintained its Equalweight rating on shares of Futu Holdings...
Progressive reports steady May growth, combined ratio rises By Investing.com
Investing.com· 2 hours agoThe Progressive Corporation (NYSE:PGR), a leading insurance provider, disclosed its financial...
JPMorgan’s Risk Swap Ends Up at a Familiar Place: Rival Banks
Bloomberg via Yahoo Finance· 2 days ago(Bloomberg) -- When JPMorgan Chase & Co. arranged a series of trades to shift the risk of losses...
Dyne Therapeutics COO sells over $1.3m in company stock By Investing.com
Investing.com· 16 hours agoIn a recent move that has caught the attention of investors, Susanna Gatti High, the Chief Operating...
Deutsche Bank adjusts Ares Management stock rating to Hold from Buy By Investing.com
Investing.com· 1 day agoOn Thursday, Deutsche Bank resumed coverage on Ares Management, L.P. (NYSE:ARES), adjusting its...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 1 day agoOn Thursday, Piper Sandler maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT)...